Related Experiment Video

Updated: Aug 15, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

[Severe hyperkalemia associated to the use of losartan and spironolactone: case report]

Ronald Kauffmann1, Rodrigo Orozco, Juan Carlos Venegas

  • 1Unidad de Cuidados Coronarios e Intermedio Coronario, Clínica Las Condes, Santiago, Chile. roka@clinicalascondes.cl

Revista Medica De Chile
|September 16, 2005
PubMed

Insights

Severe hyperkalemia is a risk of common hypertension and heart failure drugs. An 84-year-old patient on losartan and spironolactone developed life-threatening hyperkalemia, requiring intensive care and hemodialysis.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Angiotensin converting enzyme inhibitors, angiotensin receptor antagonists, and aldosterone antagonists are frequently prescribed for hypertension and cardiac failure.
  • Hyperkalemia is a known complication associated with these drug classes.

Observation:

  • An 84-year-old female patient was treated with losartan (50 mg/day) and spironolactone (25 mg/day).
  • She presented with severe hyperkalemia (8.4 mEq/l), bradycardia, drowsiness, and respiratory depression.

Findings:

  • The patient required emergent hemodialysis due to the severity of hyperkalemia.
  • Mechanical ventilatory support was necessary to manage respiratory depression.

Implications:

  • This case highlights the critical need for vigilant monitoring of potassium levels in patients receiving combined renin-angiotensin-aldosterone system inhibitors.
  • Prompt recognition and management, including renal replacement therapy, are crucial for favorable outcomes in severe drug-induced hyperkalemia.

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...